The Supreme Court will hear an appeal by a coalition of 20 mainly Democratic states, which are hoping for a reversal of a Fifth Circuit Court of Appeals ruling that held the Affordable Care Act’s (ACA) individual mandate is unconstitutional and called into question whether the remaining provisions of the law could still stand. However, a decision will not come until after the November 2020 presidential election.
The Supreme Court agreed Monday to a hear an appeal by a coalition of 20 mainly Democratic states, which are hoping for a reversal of a Fifth Circuit Court of Appeals ruling, which held the Affordable Care Act’s individual mandate is unconstitutional and called into question whether the remaining provisions of the law could still stand.
Among those provisions, of course, are the Biologics Price Competition and Innovation Act (BPCIA). The Department of Justice had argued that the Fifth Circuit should not only affirm that decision, but it should further find that other ACA provisions should also be struck down if the individual mandate was not severable from the rest of the statute.
Any effect on the BPCIA will hinge on the question of severability, observers have said.
In a statement, AARP’s Nancy LeaMond, executive vice president and chief advocacy and engagement officer praised the decision to review the case, Texas v Azar.
“We urge the Court to uphold the ACA by overturning the lower appellate court’s decision,” she said. "A final ruling by the Supreme Court is needed to end years of uncertainty for millions of Americans who worry that they will lose access to critical health care coverage and essential consumer protections. It would also end the uncertainty for insurers and state and local governments who must make advance decisions each year about participating in the ACA Marketplaces and other ACA programs.”
However, a decision in the case will not come until after the November 2020 presidential election. The new term for the court does not begin until October.
There are no changes to the ACA while the case continues.
California Attorney General Xavier Becerra, leading a coalition of 20 states and Washington DC, applauded the high court’s decision. In a statement, his office said it urged the court to take up the case to “resolve the uncertainty created by the Fifth Circuit decision, which threatens the health of millions of Americans, as well as doctors, clinics, and the healthcare market.”
At issue is whether the other parts of the law can survive without the mandate; the Republican-led states, led by Texas, said that when the tax penalty was eliminated under President Donald Trump's 2017 tax cut package, it also made the ACA unconstitutional. Democratic states opposed the challenge, saying that reducing the tax penalty to zero did not eliminate the requirement.
“The Fifth Circuit correctly applied existing US Supreme Court precedent when they ruled that the individual mandate itself was unconstitutional, said Texas Attorney General Ken Paxton in a statement. “Without the individual mandate, the entire law becomes unsupportable. The federal government cannot order private citizens to purchase subpar insurance that they don’t want, and I look forward to finally settling the matter before the US Supreme Court.”
Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan
June 17th 2025Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
Biosimilar Cases to Watch: Prolia/Xgeva and Denosumab Competitors
March 11th 2025The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and launches anticipated to start in May 2025, while ongoing patent litigation continues to shape the competitive landscape.